Exhibit 23.2

NOTICE REGARDING CONSENT OF ARTHUR ANDERSEN LLP

Section 11(a) of the Securities Act of 1933, as amended (the "Securities Act"), provides that if any part of a registration statement, at the time such
part becomes effective, contains an untrue statement of a material fact or an omission to state a material fact required to be stated therein or necessary to make the statements therein not
misleading, any person acquiring a security pursuant to such registration statement (unless it is proved that at the time of such acquisition such person knew of such untruth or omission) may sue,
among others, every accountant who has consented to be named as having prepared or certified any part of the registration statement, or as having prepared or certified any report or valuation which is
used in connection with the registration statement, with respect to the statement in such registration statement, report or valuation which purports to have been prepared or certified by the
accountant.

This
Annual Report on Form 10-K is incorporated by reference into Registration Statement File Nos. 333-104586, 333-66365, 333-03725
and 333-109340 (the "Registration Statements") of NeoPharm, Inc. ("NeoPharm") and, for purposes of determining any liability under the Securities Act, is deemed to be a new
registration statement for each Registration Statement into which it is incorporated by reference. As recommended by NeoPharm's Audit Committee, NeoPharm's Board of directors dismissed Arthur Andersen
LLP ("Andersen") on May 3, 2002, effective immediately, as NeoPharm's independent accountants. See NeoPharm's Current Report on Form 8-K/A filed May 14, 2002 for more
information.

After
reasonable efforts, NeoPharm has been unable to obtain Andersen's written consent to the incorporation by reference into the Registration Statements of its audit reports with
respect to NeoPharm's financial statements as of and for the fiscal years ended December 31, 2001 and 2000. Under these circumstances, Rule 437a under the Securities Act permits NeoPharm
to file this Form 10-K without a written consent from Andersen. However, as a result, with respect to transactions in NeoPharm securities pursuant to the Registration Statements
that occur subsequent to the date this Annual Report on Form 10-K is filed with the Securities and Exchange Commission, Andersen may not have any liability under
Section 11(a) of the Securities Act for any untrue statements of a material fact contained in the financial statements audited by Andersen or any omission of a material fact required to be
stated therein.

Accordingly,
you might be unable to assert a claim against Andersen under Section 11(a) of the Securities Act because it has not consented to the incorporation by reference into
the Registration Statements of the copies of its audit reports for the period ending December 31, 2001 which are reproduced herein. To the extent provided in section 11(b)(3)(C) of the
Securities Act, however, other persons who are potentially subject to liability under Section 11(a) of the Securities Act, including NeoPharm's officers and directors, may still rely on
Andersen's original audit reports as being made by an expert for purposes of establishing a due diligence defense under Section 11(b) of the Securities Act. These facts may have the effect of
limiting the ability of NeoPharm investors to recover any losses suffered in connection with the purchase or sale of NeoPharm securities due to material inaccuracies or omissions contained in the
financial statements reproduced herein for the period ending December 31, 2001.

---

QuickLinks